Trial · NCT03852433
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Sustained Virological Response at Week 24 After the Scheduled End of Treatment (SVR24) | Pegylated Interferon Alfa-2a (PEG-IFN Alfa) | 16.7 | 95% Confidence Interval 4.7 to 37.4 | percentage of participants | |
| Percentage of Participants With Sustained Virological Response at Week 24 After the Scheduled End of Treatment (SVR24) | Bulevirtide 2 mg/Day + PEG-IFN Alfa | 32.0 | 95% Confidence Interval 19.5 to 46.7 | percentage of participants | |
| Percentage of Participants With Sustained Virological Response at Week 24 After the Scheduled End of Treatment (SVR24) | Bulevirtide 10 mg/Day + PEG-IFN Alfa | 46.0 | 95% Confidence Interval 31.8 to 60.7 | percentage of participants | |
| Percentage of Participants With Sustained Virological Response at Week 24 After the Scheduled End of Treatment (SVR24) | Bulevirtide 10 mg/Day | 12.0 | 95% Confidence Interval 4.5 to 24.3 | percentage of participants | |
| Percentage of Participants With Undetectable HDV RNA at Week 48 | Pegylated Interferon Alfa-2a (PEG-IFN Alfa) | 20.8 | 95% Confidence Interval 7.1 to 42.2 | percentage of participants | |
| Percentage of Participants With Undetectable HDV RNA at Week 48 | Bulevirtide 2 mg/Day + PEG-IFN Alfa | 40.0 | 95% Confidence Interval 26.4 to 54.8 | percentage of participants | |
| Percentage of Participants With Undetectable HDV RNA at Week 48 | Bulevirtide 10 mg/Day + PEG-IFN Alfa | 60.0 | 95% Confidence Interval 45.2 to 73.6 | percentage of participants | |
| Percentage of Participants With Undetectable HDV RNA at Week 48 | Bulevirtide 10 mg/Day | 10.0 | 95% Confidence Interval 3.3 to 21.8 | percentage of participants | |
| Percentage of Participants With Undetectable HDV RNA at Week 96 (Arms B, C, and D Only) | Bulevirtide 2 mg/Day + PEG-IFN Alfa | 44.0 | 95% Confidence Interval 30.0 to 58.7 | percentage of participants | |
| Percentage of Participants With Undetectable HDV RNA at Week 96 (Arms B, C, and D Only) | Bulevirtide 10 mg/Day + PEG-IFN Alfa | 70.0 | 95% Confidence Interval 55.4 to 82.1 | percentage of participants | |
| Percentage of Participants With Undetectable HDV RNA at Week 96 (Arms B, C, and D Only) | Bulevirtide 10 mg/Day | 22.0 | 95% Confidence Interval 11.5 to 36.0 | percentage of participants | |
| Percentage of Participants With Combined Response at Week 24 After the Scheduled End of Treatment | Pegylated Interferon Alfa-2a (PEG-IFN Alfa) | 20.8 | 95% Confidence Interval 7.1 to 42.2 | percentage of participants | |
| Percentage of Participants With Combined Response at Week 24 After the Scheduled End of Treatment | Bulevirtide 2 mg/Day + PEG-IFN Alfa | 36.0 | 95% Confidence Interval 22.9 to 50.8 | percentage of participants | |
| Percentage of Participants With Combined Response at Week 24 After the Scheduled End of Treatment | Bulevirtide 10 mg/Day + PEG-IFN Alfa | 52.0 | 95% Confidence Interval 37.4 to 66.3 | percentage of participants | |
| Percentage of Participants With Combined Response at Week 24 After the Scheduled End of Treatment | Bulevirtide 10 mg/Day | 26.0 | 95% Confidence Interval 14.6 to 40.3 | percentage of participants | |
| Percentage of Participants With Combined Response at Week 48 After the Scheduled End of Treatment | Pegylated Interferon Alfa-2a (PEG-IFN Alfa) | 33.3 | 95% Confidence Interval 15.6 to 55.3 | percentage of participants | |
| Percentage of Participants With Combined Response at Week 48 After the Scheduled End of Treatment | Bulevirtide 2 mg/Day + PEG-IFN Alfa | 32.0 | 95% Confidence Interval 19.5 to 46.7 | percentage of participants | |
| Percentage of Participants With Combined Response at Week 48 After the Scheduled End of Treatment | Bulevirtide 10 mg/Day + PEG-IFN Alfa | 46.0 | 95% Confidence Interval 31.8 to 60.7 | percentage of participants | |
| Percentage of Participants With Combined Response at Week 48 After the Scheduled End of Treatment | Bulevirtide 10 mg/Day | 18.0 | 95% Confidence Interval 8.6 to 31.4 | percentage of participants | |
| Percentage of Participants With Sustained Virological Response 48 After the Scheduled End of Treatment (SVR 48) | Pegylated Interferon Alfa-2a (PEG-IFN Alfa) | 25.0 | 95% Confidence Interval 9.8 to 46.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03852433/results